NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Scisparc Ltd. SPRC
10 fiscal years on record · USD · FY2024 reported
SEC FILINGS ONLY
Revenue · FY2024
$1.3M
▼ 54.6% vs FY2023
EPS · FY24
$1.28
Dividend / sh · FY24
—
Payout · FY24
—
ROE · FY24
-79.7%
Net margin · FY24
-481.2%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 1.3M
Revenue, FY2024 · full 10-year series below
Revenue
Net income
The company lost 481 cents on every revenue dollar this year.
Per share
USD 1.28
Diluted EPS, FY2024
EPS
The company pays no cash dividend.
Profitability
-79.7%
Return on equity, FY2024
ROE
Operating margin-560.2%
Net margin-481.2%
Return on assets-58.4%
Each USD of equity lost 80 cents this year.
Returned to shareholders
—
returned in FY2024 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.01B
Shares outstanding, FY2024
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 10.3M
total assets, end of FY2024
Total assetsUSD 10.3M
EquityUSD 8.2M
CashUSD 1.5M
Current ratio5.36×
Equity funds 79% of total assets.
History
10 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
Revenue $B
0.0
0.0
0.0
·
·
·
·
·
·
·
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
EBITDA $B
·
·
·
·
·
·
·
·
·
·
Income tax $B
−0.0
0.0
0.0
·
·
·
−0.0
·
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
EPS, diluted $
1.28
14.43
−14.82
−73.58
0.11
0.60
1.20
·
·
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
ROE %
−79.7
−72.8
−40.2
·
25250.0
4709.5
208.7
74.4
·
·
Shares out B
0.01
0.00
0.00
0.00
0.00
0.01
0.14
0.14
0.04
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
23 of 25
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 2 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed